We came across a bullish thesis on MannKind Corporation on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on MNKD. MannKind Corporation's share was trading at $3.5000 as of February 25th. MNKD’s trailing and forward P/E were 49.91 and 34.36, respectively according to Yahoo Finance. Top 12 Anesthesiology Residency Programs in 2018 Cherries/Shutterstock.com MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic d ...

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the most promising penny stocks under $5 to buy. On February 24, AbCellera Biologics announced its Q4 and full-year 2025 financial results, marking a major transition into a clinical-stage biotechnology company. The firm ended the year with $75 million in total revenue, which was composed of $27 million from partnered programs and $48 million from licensing and royalties, while reporting a net loss of $146 million. This loss reflects a significant pivot to ...

Core Thesis - AbCellera Biologics Inc. is transitioning from a service-oriented antibody discovery platform to a clinical-stage biotech with proprietary drug candidates, aiming to create long-term value through internal and co-developed programs [3][4] Financial Overview - As of January 21st, AbCellera's share was trading at $3.6200, with a trailing P/E of 19.92 [1] - The company holds approximately $520 million in cash and around $680 million in total liquidity, providing a strong financial position to execute its strategy without near-term financing risk [4] Market Position and Strategy - The stock has seen a decline of over 90% from its post-IPO highs, currently trading near $4.50, reflecting skepticism about the platform's ability to translate discovery into drugs rather than a deterioration of underlying assets [4] - AbCellera's internal pipeline includes Phase 1 assets ABCL635 and ABCL575, targeting large markets with differentiated dosing profiles, with initial clinical readouts expected in 2026 [5] Growth Potential - The company has a diversified royalty portfolio with over 100 partnered programs, 18 of which are in the clinic, providing long-duration upside with limited incremental capital [6] - The combination of deep liquidity, validated technology, and an expanding internal pipeline creates a compelling asymmetric opportunity for substantial upside from current depressed levels [7]

Core Insights - Peter Thiel, with a net worth of approximately $27 billion, is recognized for his successful ventures including PayPal and Palantir Technologies, as well as his effective financial planning strategies, particularly his Roth IRA which amassed $1 billion [1][3][7] Investment Strategy - Thiel's Roth IRA growth was primarily driven by early investments in PayPal shares and private equity in startups prior to their public offerings, showcasing a strategy focused on high-growth emerging technology companies [3][5] - His portfolio was diversified across stocks, bonds, and alternative assets, emphasizing the importance of not concentrating investments in a single area [4][5] - Regular reviews and rebalancing of his holdings allowed Thiel to capitalize on market opportunities and adjust his investments as needed [3][5] Private Equity Investments - Thiel included private equity investments in his strategy, particularly in startups, which provided significant returns when these companies went public, exemplified by his involvement with AbCellera Biologics [5] Accessibility to Information - The difference in Thiel's investment success compared to average investors lies in his access to superior information and assets, enabling him to invest early in companies that later experienced exponential growth [6]

Core Insights - AbCellera will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [1] - A live audio webcast of the presentation will be available on AbCellera's Investor Relations website, with a replay accessible afterward [1] Company Overview - AbCellera is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines [2] - The company's areas of focus include endocrinology, women's health, immunology, and oncology [2] - More information about the company can be found on their website [2]

Core Insights - AbCellera Biologics Inc. (NASDAQ:ABCL) is experiencing a decline of over 23% since its fiscal Q3 2025 business update, yet analysts maintain a bullish outlook with a 12-month average price target of $8.5, indicating a potential upside of 144.96% from current levels [1]. Financial Performance - The company reported a year-over-year revenue growth of 37.62%, reaching $8.96 million, which exceeded estimates by $2.62 million. However, the earnings per share (EPS) of negative $0.19 fell short of expectations by $0.03 [3]. Strategic Direction - AbCellera is shifting its strategy from partnerships to developing its own clinical assets while still valuing existing partnerships with major pharmaceutical companies like Lilly and AbVie. This strategic pivot aims to leverage its capabilities and technologies for internal development [4]. Product Development - The company is focused on discovering and developing antibody-based medicines targeting cancer, metabolic/endocrine conditions, and autoimmune disorders, utilizing an AI-powered platform for rapid single-cell screening [5]. Analyst Ratings - On November 19, David Martin, PhD, from Bloom Burton reiterated a Buy rating with a price target of $9. Earlier, Srikripa Devarakonda from Truist Financial also maintained a Buy rating without specifying a price target [2].

Core Insights - Several biotech and life sciences companies experienced significant gains in after-hours trading on November 26, indicating strong investor interest despite a quiet news cycle [1] Company Summaries - Modular Medical, Inc. (MODD) shares increased by 11.51% to $0.4380 after a previous decline of 1.80% at the close, following the IRB approval for its Pivot insulin delivery system study announced on November 17 [2] - Standard BioTools Inc. (LAB) saw a 4.90% rise to $1.50 after a 0.70% gain during regular trading, following a strategic collaboration with Molecular Instruments announced on November 19 [3] - Werewolf Therapeutics, Inc. (HOWL) rose 4.39% to $1.0199 after a strong 7.33% gain during regular trading, reflecting continued investor optimism despite no new updates [4] - Cogent Biosciences, Inc. (COGT) climbed 6.09% to $42.85 in after-hours trading, building on a 1.69% rise during regular trading, indicating strong investor confidence in its pipeline [5] - Longeveron Inc. (LGVN) shares increased by 4.59% to $0.6772, extending gains from a 7.02% rise during regular trading, with upcoming presentation of Alzheimer's study results at CTAD 2025 highlighting ongoing research [6] - AbCellera Biologics Inc. (ABCL) gained 3.85% to $3.78 after a 0.55% increase during regular trading, reflecting renewed investor interest in its antibody discovery platform [7]

Core Viewpoint - AbCellera Biologics Inc. is recommended as a Buy by Stifel Nicolaus despite reporting a wider-than-expected net loss in Q3 2024, with a price target set at $7 [1][2]. Financial Performance - The company reported a net loss of $57.1 million in Q3 2024, compared to a net loss of $51.1 million in the same quarter last year, indicating a deterioration in financial performance [2]. - Research and development (R&D) expenses increased significantly to $55 million from $41 million year-over-year [2]. - Revenue for the quarter was $9 million, up from $6.5 million in the same quarter last year, showing growth in sales [3]. Operational Highlights - AbCellera achieved key milestones, including the commencement of operations at its new clinical manufacturing facility [3]. - The company is advancing its pipeline with two lead programs, ABCL635 and ABCL575, currently in Phase 1 clinical trials [3][4]. Liquidity Position - The company ended the quarter with approximately $680 million in available liquidity, which will be utilized to execute its strategic plans and advance its clinical studies [4]. Company Overview - AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines using an integrated technology platform [5].

Core Insights - AbCellera Biologics Inc. is transitioning from a partnership model to developing its own clinical assets, supported by a strong financial position [1][2] - The company has over $500 million in cash and equivalents, focusing on developing ABCL635 for menopausal hot flashes and ABCL575 for atopic dermatitis [2][3] - Analysts from TD Cowen and Stifel Nicolaus have reiterated a Buy rating for AbCellera, with a price target of $7 [3] Company Overview - AbCellera Biologics Inc. is a clinical-stage biotechnology company that specializes in discovering and developing antibody-based medicines for various diseases, including cancer and autoimmune disorders [4]

Core Insights - Several biotechnology and pharmaceutical stocks experienced significant price increases during after-hours trading, driven by upcoming data releases, recent earnings reports, and prior corporate updates [1] Company Summaries - InflaRx N.V. (IFRX) saw a surge of 63.41% to $2.01 after hours, following a 2.50% gain at the close, due to plans to release topline data from its Phase 2a trial of oral C5aR inhibitor INF904, expected on Monday morning alongside its third-quarter financial results [2] - Rallybio Corp. (RLYB) rose 12.84% to $0.71 after reporting a third-quarter net income of $16.0 million, or $0.36 per share, reversing a prior-year loss of $11.5 million, although revenue for the quarter was $0.2 million, slightly below the $0.3 million reported in the same period last year [3] - FibroBiologics Inc. (FBLG) climbed 13.51% to $0.40 after hours, building on a 5.13% gain during regular trading, following the release of its third-quarter financial results and a corporate update on October 31 [4] - AbCellera Biologics Inc. (ABCL) advanced 6.51% to $4.16 after hours, recovering from a 13.69% decline earlier in the day, reporting a third-quarter net loss of $57.1 million, or $(0.19) per share, compared to a loss of $51.1 million in the same quarter last year, while revenue increased to $9.0 million from $6.5 million year-over-year [5] - BioRestorative Therapies Inc. (BRTX) gained 11.68% to $1.53 in after-hours trading, following a Notice of Allowance from the Japanese Patent Office for its ThermoStem platform announced on October 27, with third-quarter results scheduled for release on November 12 [6] - Cellectis S.A. (CLLS) rose 6.58% to $3.40 after hours, reporting a third-quarter net income of $589 thousand, or $0.01 per share, compared to a $23.1 million loss in the prior year, with total revenues and other income more than doubling to $37.2 million from $18.1 million [7]